Polymeric nanoparticles for the selective therapy of inflammatory bowel disease

Methods in Enzymology

Volumn 508, Issue , 2012, Pages 377-397

  Wachsmann, Philip ^a   Lamprecht, Alf ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Bioadhesion to inflamed tissue; Colitis targeting; Colonic delivery; Epithelial EPR effect; Nanoparticles in anti inflammatory therapy

Indexed keywords

ALKALINE PHOSPHATASE; AZATHIOPRINE; BUDESONIDE; CHLORPROMAZINE; CORTICOSTEROID; CYCLOSPORIN; CYTOCHALASIN B; CYTOKINE; DEXTRAN SULFATE; DRUG CARRIER; FILIPIN; FLUTICASONE; GENISTEIN; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 8; MESALAZINE; MYELOPEROXIDASE; NANOPARTICLE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; OLSALAZINE; OXAZOLONE; POLYGLACTIN; POLYMER; POLYMERIC NANOPARTICLE; SALAZOSULFAPYRIDINE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INTERACTION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TRANSPORT; ENTERITIS; FECES ANALYSIS; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; NONHUMAN; OUTCOME ASSESSMENT; PARTICLE SIZE; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; REMISSION; TREATMENT INDICATION; ULCERATIVE COLITIS; ZETA POTENTIAL;

MURINAE;

EID: 84859065561     PISSN: 00766879     EISSN: 15577988     Source Type: Book Series    
DOI: 10.1016/B978-0-12-391860-4.00019-7     Document Type: Chapter

References (72)

1. M.M.A. Abdel-Mottaleb, and A. Lamprecht Standardized in vitro drug release test for colloidal drug carriers using modified USP dissolution apparatus I Drug Dev. Ind. Pharm. 37 2011 178 184
2. A. Anas, T. Okuda, N. Kawashima, K. Nakayama, T. Itoh, M. Ishikawa, and V. Biju Clathrin-mediated endocytosis of quantum dot-peptide conjugates in living cells ACS Nano 3 2009 2419 2429
3. L.F.A. Asghar, and S. Chandran Multiparticulate formulation approach to colon specific drug delivery: Current perspectives J. Pharm. Pharm. Sci. 9 2006 327 338 (Pubitemid 46614339)
4. D.C. Baumgart, and S.R. Carding Inflammatory bowel disease: Cause and immunobiology Lancet 369 2007 1627 1640 (Pubitemid 46722636)
5. M.D. Blanco, and M.J. Alonso Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres Eur. J. Pharm. Biopharm. 43 1997 287 294
6. R. Bodmeier, and H. Cheng Indomethacin polymeric nanosuspensions prepared by microfluidization J. Control. Release 12 1990 223 233 (Pubitemid 20162633)
7. G. Bouma, and W. Strober The immunological and genetic basis of inflammatory bowel disease Nat. Rev. Immunol. 3 2003 521 533 (Pubitemid 37328672)
8. S.R. Brant, C.I. Panhuysen, D. Nicolae, D.M. Reddy, D.K. Bonen, R. Karaliukas, L. Zhang, E. Swanson, L.W. Datta, T. Moran, G. Ravenhill, and R.H. Duerr MDR1 Ala893 polymorphism is associated with inflammatory bowel disease Am. J. Hum. Genet. 73 2003 1282 1292 (Pubitemid 38037422)
9. D. Burger, and S. Travis Conventional medical management of inflammatory bowel disease Gastroenterology 140 2011 1827.e2-1837.e2
10. E. Cario Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2 Gut 54 2005 1182 1193 (Pubitemid 41025918)
11. B. Chassaing, and A. Darfeuille-Michaud The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases Gastroenterology 140 2011 1720.e3-1728e3
12. F. Chellat, Y. Merhi, A. Moreau, and L. Yahia Therapeutic potential of nanoparticulate systems for macrophage targeting Biomaterials 26 2005 7260 7275 (Pubitemid 41133578)
13. M. Chorny, I. Fishbein, H.D. Danenberg, and G. Golomb Lipophilic drug loaded nanospheres prepared by nanoprecipitation: Effect of formulation variables on size, drug recovery and release kinetics J. Control. Release 83 2002 389 400 (Pubitemid 35223261)
14. M.J.D. Clift, B. Rothen-Rutishauser, D.M. Brown, R. Duffin, K. Donaldson, L. Proudfoot, K. Guy, and V. Stone The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line Toxicol. Appl. Pharmacol. 232 2008 418 427
15. M.J.D. Clift, S. Bhattacharjee, D.M. Brown, and V. Stone The effects of serum on the toxicity of manufactured nanoparticles Toxicol. Lett. 198 2010 358 365
16. J. Davda, and V. Labhasetwar Characterization of nanoparticle uptake by endothelial cells Int. J. Pharm. 233 2002 515 519
17. S. Desgouilles, C. Vauthier, D. Bazile, J. Vacus, J. Grossiord, M. Veillard, and P. Couvreur The design of nanoparticles obtained by solvent evaporation: A comprehensive study Langmuir 19 2003 9504 9510
18. J. Fallingborg, L.A. Christensen, B.A. Jacobsen, and S.N. Rasmussen Very low intraluminal colonic pH in patients with active ulcerative colitis Dig. Dis. Sci. 38 1993 1989 1993 (Pubitemid 23336560)
19. N. Garrido-Mesa, D. Camuesco, B. Arribas, M. Comalada, E. Bailón, M. Cueto-Sola, P. Utrilla, A. Nieto, A. Zarzuelo, M.E. Rodríguez-Cabezas, and J. Gálvez The intestinal anti-inflammatory effect of minocycline in experimental colitis involves both its immunomodulatory and antimicrobial properties Pharmacol. Res. 63 2011 308 319
20. N. Gassler, C. Rohr, A. Schneider, J. Kartenbeck, A. Bach, N. Obermüller, H.F. Otto, and F. Autschbach Inflammatory bowel disease is associated with changes of enterocytic junctions Am. J. Physiol. Gastrointest. Liver Physiol. 281 2001 G216 G228
21. M. Gaumet, R. Gurny, and F. Delie Localization and quantification of biodegradable particles in an intestinal cell model: The influence of particle size Eur. J. Pharm. Sci. 36 2009 465 473
22. P. Gionchetti, F. Rizzello, F. Habal, C. Morselli, C. Amadini, R. Romagnoli, and M. Campieri Standard treatment of ulcerative colitis Dig. Dis. 21 2003 157 167 (Pubitemid 37323494)
23. S.E.A. Gratton, P.A. Ropp, P.D. Pohlhaus, J.C. Luft, V.J. Madden, M.E. Napier, and J.M. DeSimone The effect of particle design on cellular internalization pathways Proc. Natl. Acad. Sci. USA 105 2008 11613 11618
24. J. Halfvarson, L. Bodin, C. Tysk, E. Lindberg, and G. Järnerot Inflammatory bowel disease in a Swedish twin cohort: A long-term follow-up of concordance and clinical characteristics Gastroenterology 124 2003 1767 1773 (Pubitemid 36666773)
25. J.G. Hardy, S. Davis, R. Khosla, and C. Robertson Gastrointestinal transit of small tablets in patients with ulcerative colitis Int. J. Pharm. 48 1988 79 82
26. G. Hartmann, C. Bidlingmaier, B. Siegmund, S. Albrich, J. Schulze, K. Tschoep, A. Eigler, H.A. Lehr, and S. Endres Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice J. Pharmacol. Exp. Ther. 292 2000 22 30 (Pubitemid 30026352)
27. F. Heller, I.J. Fuss, E.E. Nieuwenhuis, R.S. Blumberg, and W. Strober Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells Immunity 17 2002 629 638 (Pubitemid 35351508)
28. R.F. Henderson, J.M. Benson, F.F. Hahn, C.H. Hobbs, R.K. Jones, J.L. Mauderly, R.O. McClellan, and J.A. Pickrell New approaches for the evaluation of pulmonary toxicity: Bronchoalveolar lavage fluid analysis Fundam. Appl. Toxicol. 5 1985 451 458 (Pubitemid 15026296)
29. H. Hillaireau, and P. Couvreur Nanocarriers' entry into the cell: Relevance to drug delivery Cell. Mol. Life Sci. 66 2009 2873 2896
30. G.T. Ho, E.R. Nimmo, A. Tenesa, J. Fennell, H. Drummond, C. Mowat, I.D. Arnott, and J. Satsangi Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis Gastroenterology 128 2005 288 296 (Pubitemid 40431082)
31. J.C. Hoffmann, N.N. Pawlowski, A.A. Kühl, W. Höhne, and M. Zeitz Animal models of inflammatory bowel disease: An overview Pathobiology 70 2002 121 130
32. A.R. Jurjus, N.N. Khoury, and J.M. Reimund Animal models of inflammatory bowel disease J. Pharmacol. Toxicol. Methods 50 2004 81 92 (Pubitemid 39286320)
33. G. Lahat, D. Halperin, E. Barazovsky, I. Shalit, M. Rabau, J. Klausner, and I. Fabian Immunomodulatory effects of ciprofloxacin in TNBS-induced colitis in mice Inflamm. Bowel Dis. 13 2007 557 565 (Pubitemid 46799639)
34. S.K. Lai, K. Hida, S.T. Man, C. Chen, C. Machamer, T.A. Schroer, and J. Hanes Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway Biomaterials 28 2007 2876 2884 (Pubitemid 46482662)
35. A. Lamprecht Selective nanoparticle adhesion can enhance colitis therapy Nat. Rev. Gastroenterol. Hepatol. 7 2010 311 312
36. A. Lamprecht, N. Ubrich, M. Hombreiro Pérez, C.M. Lehr, M. Hoffman, and P. Maincent Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification Int. J. Pharm. 184 1999 97 105 (Pubitemid 29308999)
37. A. Lamprecht, U. Schäfer, and C.M. Lehr Size-dependent bioadhesion of micro-and nanoparticulate carriers to the inflamed colonic mucosa Pharm. Res. 18 2001 788 793 (Pubitemid 32783514)
38. A. Lamprecht, H. Yamamoto, H. Takeuchi, and Y. Kawashima Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats J. Pharmacol. Exp. Ther. 315 2005 196 202 (Pubitemid 41380512)
39. A. Lamprecht, H. Yamamoto, H. Takeuchi, and Y. Kawashima A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles J. Control. Release 104 2005 337 346 (Pubitemid 40724934)
40. H. Laroui, G. Dalmasso, H.T. Nguyen, Y. Yan, S.V. Sitaraman, and D. Merlin Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model Gastroenterology 138 2010 843 853
41. F. Leonard, E.M. Collnot, and C.M. Lehr A 3-dimensional co-culture of enterocytes, macrophages and dendritic cells to model the inflamed intestinal mucosa in vitro Mol. Pharm. 7 2010 2103 2119
42. T. Lindl, and G. Gstraunthaler Zell- und Gewebekultur 6th edn. 2008 Spektrum Akademischer Verlag Heidelberg
43. M.J. Lodes, Y. Cong, C.O. Elson, R. Mohamath, C.J. Landers, S.R. Targan, M. Fort, and R.M. Hershberg Bacterial flagellin is a dominant antigen in Crohn disease J. Clin. Invest. 113 2004 1296 1306 (Pubitemid 39069929)
44. E.V. Loftus Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences Gastroenterology 126 2004 1504 1517
45. A. Macpherson, U.Y. Khoo, I. Forgacs, J. Philpott-Howard, and I. Bjarnason Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria Gut 38 1996 365 375 (Pubitemid 26074316)
46. K. Mladenovska, R. Raicki, E. Janevik, T. Ristoski, M. Pavlova, Z. Kavrakovski, M. Dodov, and K. Goracinova Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles Int. J. Pharm. 342 2007 124 136 (Pubitemid 47259341)
47. T. Mosmann Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63 (Pubitemid 14203433)
48. R.H. Müller Zetapotential und Partikelladung in der Laborpraxis 1996 Wissenschaftliche Verlagsgesellschaft mbH Stuttgart
49. M.F. Neurath, I. Fuss, B.L. Kelsall, E. Stüber, and W. Strober Antibodies to interleukin 12 abrogate established experimental colitis in mice J. Exp. Med. 182 1995 1281 1290
50. B. Newman, and K.A. Siminovitch Recent advances in the genetics of inflammatory bowel disease Curr. Opin. Gastroenterol. 21 2005 401 407 (Pubitemid 40961164)
51. Y. Ogura, D.K. Bonen, N. Inohara, D.L. Nicolae, F.F. Chen, R. Ramos, H. Britton, T. Moran, R. Karaliuskas, R.H. Duerr, J.P. Achkar, and S.R. Brant A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease Nature 411 2001 603 606 (Pubitemid 32531409)
52. D.E. Owens, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 2006 93 102 (Pubitemid 41773257)
53. J. Palomäki, P. Karisola, L. Pylkkänen, K. Savolainen, and H. Alenius Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells Toxicology 267 2010 125 131
54. J. Panyam, and V. Labhasetwar Biodegradable nanoparticles for drug and gene delivery to cells and tissue Adv. Drug Deliv. Rev. 55 2003 329 347 (Pubitemid 36297053)
55. J. Panyam, S.K. Sahoo, S. Prabha, T. Bargar, and V. Labhasetwar Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(d,l-lactide-co-glycolide) nanoparticles Int. J. Pharm. 262 2003 1 11 (Pubitemid 36966688)
56. D. Pertuit, B. Moulari, T. Betz, A. Nadaradjane, D. Neumann, L. Ismaïli, B. Refouvelet, Y. Pellequer, and A. Lamprecht 5-Amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease J. Control. Release 123 2007 211 218 (Pubitemid 350007824)
57. C. Pinto Reis, R.J. Neufeld, A.J. Ribeiro, and F. Veiga Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles Nanomedicine 2 2006 8 21
58. D. Quintanar-Guerrero, E. Allémann, H. Fessi, and E. Doelker Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers Drug Dev. Ind. Pharm. 24 1998 1113 1128 (Pubitemid 28546092)
59. J. Rejman, V. Oberle, I. Zuhorn, and D. Hoekstra Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis Biochem. J. 377 2004 159 169 (Pubitemid 38114443)
60. R.B. Sartor Mechanisms of disease: Pathogenesis of Crohn's disease and ulcerative colitis Nat. Clin. Pract. Gastroenterol. Hepatol. 3 2006 390 407 (Pubitemid 44018812)
61. V. Schäfer, H. von Briesen, R. Andreesen, A. Steffan, C. Royer, S. Tröster, J. Kreuter, and H. Rübsamen-Waigmann Phagocytosis of nanoparticles by human immunodeficiency virus (HlV)-infected macrophages: A possibility for antiviral drug targeting Pharm. Res. 9 1992 541 546
62. C.A. Seldenrijk, H.A. Drexhage, S.G. Meuwissen, S.T. Pals, and C.J. Meijer Dendritic cells and scavenger macrophages in chronic inflammatory bowel disease Gut 30 1989 484 491
63. W. Strober, and I.J. Fuss Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases Gastroenterology 140 2011 1756.e1-1767.e1
64. A. Swidsinski, V. Loening-Baucke, F. Theissig, H. Engelhardt, S. Bengmark, S. Koch, H. Lochs, and Y. Dörffel Comparative study of the intestinal mucus barrier in normal and inflamed colon Gut 56 2007 343 350 (Pubitemid 46579762)
65. Y. Tabata, and Y. Ikada Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage Biomaterials 9 1988 356 362
66. T. Tanoue, Y. Nishitani, K. Kanazawa, T. Hashimoto, and M. Mizuno In vitro model to estimate gut inflammation using co-cultured Caco-2 and RAW264.7 cells Biochem. Biophys. Res. Commun. 374 2008 565 569
67. C. Vauthier, and K. Bouchemal Methods for the preparation and manufacture of polymeric nanoparticles Pharm. Res. 26 2009 1025 1058
68. V. Villari, and N. Micali Light scattering as spectroscopic tool for the study of disperse systems useful in pharmaceutical sciences J. Pharm. Sci. 97 2008 1703 1730
69. Z. Wang, C. Tiruppathi, R.D. Minshall, and A.B. Malik Size and dynamics of caveolae studied using nanoparticles in living endothelial cells ACS Nano 3 2009 4110 4116
70. C.N. Williams, G. Haber, and J.A. Aquino Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories Dig. Dis. Sci. 32 1987 71S 75S
71. S. Wirtz, and M.F. Neurath Mouse models of inflammatory bowel disease Adv. Drug Deliv. Rev. 59 2007 1073 1083 (Pubitemid 47615208)
72. Y. Xia, and J.L. Zweier Measurement of myeloperoxidase in leukocyte-containing tissues Anal. Biochem. 245 1997 93 96 (Pubitemid 27053423)